Athena Countouriotis
Director/Board Member at BIOMARIN PHARMACEUTICAL INC.
Net worth: 215 916 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Asa Abeliovich | M | 60 |
Leal Therapeutics, Inc.
 Leal Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Leal Therapeutics, Inc. develops novel therapeutics for patients with major disorders of the central nervous systems. | - |
| Jean-Jacques Bienaimé | M | 70 | 19 years | |
| Frederick Vogt | M | 50 | 8 years | |
| Edgar Cale | M | 60 | 5 years | |
| Jean-Marc Bellemin | M | 51 | 4 years | |
| William Chou | M | 51 | 2 years | |
| Liam Ratcliffe | M | 60 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 5 years |
| Laura Shawver | M | 66 |
Capstan Therapeutics, Inc.
 Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Randy Meier | M | 65 | 18 years | |
| Merrill McPeak | M | 88 | 13 years | |
| Maxine Gowen | M | 66 | 3 years | |
| Gini Deshpande | M | - |
NuMedii, Inc.
 NuMedii, Inc. Miscellaneous Commercial ServicesCommercial Services NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA. | 16 years |
| Alexander Hardy | M | 56 | 1 years | |
| Jeffrey Henderson | M | 59 | 9 years | |
| Patrick P. Zarrinkar | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Sandipkumar S. Kapadia | M | 53 | 5 years | |
| Dennis Joseph Slamon | M | 75 | 10 years | |
| Daniel K. Treiber | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Willard Dere | M | 70 | 8 years | |
| Elizabeth Anderson | F | 66 | 5 years | |
| David Pyott | M | 70 | 8 years | |
| James M. Wilson | M | - | 7 years | |
| Derrell Porter | M | 53 | 3 years | |
| Barbara Bodem | F | 56 | 1 years | |
| Philip Lo Scalzo | M | - | 17 years | |
| Sara Pellegrino | F | - | - | |
| Nancy Whiting | M | 51 |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | 3 years |
| Brian Hodous | M | - |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | - |
| Haig Aghajanian | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | 2 years |
| Karen Smith | F | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Kathleen Borthwick | F | 48 | 3 years | |
| Stuart M. Henderson | M | - | 3 years | |
| Atul J. Butte | M | - |
NuMedii, Inc.
NuMedii, Inc. Miscellaneous Commercial ServicesCommercial Services NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA. | 16 years |
| Saqib Islam | M | 54 | 5 years | |
| Michael Kamarck | M | 73 | 2 years | |
| Wendy Yarno | F | 68 | 1 years | |
| Elaine Heron | M | 76 | 22 years | |
| V. Lawlis | M | 72 | 17 years | |
| Wayne P. Rothbaum | M | 56 | 8 years | |
| May Kin Ho | M | 71 | 3 years | |
| Brian Mueller | M | 50 | 22 years | |
| Mark Alles | M | 64 | 2 years | |
| Michael Weiser | M | 61 | 6 years | |
| Ryan Maynard | M | 54 | 9 years | |
| Mark Enyedy | M | 60 | 1 years | |
| Iain Dukes | M | 65 | 8 years | |
| Robert Hombach | M | 58 | 7 years | |
| Stuart Bunting | M | - | 16 years | |
| Jeff Ajer | M | 61 | 19 years | |
| Mohammad Hirmand | M | 54 |
Avenzo Therapeutics, Inc.
 Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | - |
| George Davis | M | 53 | 20 years | |
| Humaira Serajuddin | F | - | 2 years | |
| Erin Burkhart | F | 45 | 2 years | |
| Raj K. Puri | M | - | 2 years | |
| Andrew Levin | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Ganesh Vedantham | M | - | 3 years | |
| Marni Kottle | F | - | - | |
| Brian Shew | M | - | 3 years | |
| Tracy Winton | F | - | 4 years | |
| Andrea Campanile | F | - | - | |
| Amy Wireman | F | - | 11 years | |
| Rajul Jain | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Henry Fuchs | M | 66 | 15 years | |
| C. Guyer | M | 62 | - | |
| Nandita Shangari | M | 43 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Traci McCarty | F | - | - | |
| Brinda Balakrishnan | M | 44 | 8 years | |
| Brad Glasscock | M | - | 12 years | |
| Dave Jacoby | M | - | 8 years | |
| Kevin Eggan | M | - | 4 years | |
| Ted Driscoll | M | 71 |
NuMedii, Inc.
NuMedii, Inc. Miscellaneous Commercial ServicesCommercial Services NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA. | - |
| Alex Fotopoulos | M | 55 | 5 years | |
| Igor Bilinsky | M | 51 | 3 years | |
| Erez Chimovits | M | 60 |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | - |
| Eduardo Von Pervieux | M | - | 16 years | |
| Michael Baran | M | - |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company that develops targeted in vivo RNA technologies to multiply therapeutic possibilities for patients. Capstan Therapeutics is based in San Diego, CA. The company's platform technology, tLNPs, delivers payloads capable of reprogramming specific cell types in vivo, including gene editing tools. The company aims to generate transformative therapies for autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. The company was founded in 2022 by Haig Aghajanian, and the CEO is Laura K. Shawver. | 2 years |
| Jen Saunders | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bill Welch | M | 62 | 2 years | |
| Bruce Goldsmith | M | 58 | 2 years | |
| Timothy Morris | M | 61 | 3 years | |
| Stephen P. Squinto | M | 67 | 4 years | |
| Kathryn Falberg | F | 63 | 9 years | |
| Amber Salzman | M | 62 | 2 years | |
| David Ramsay | M | 59 | 12 years | |
| Michael Swartzburg | M | 57 | 3 years | |
| Steven Schwartz | M | 62 | 11 years | |
| Harry Leonhardt | M | 67 | 5 years | |
| Maria Fardis | M | 56 | 5 years | |
| Samuel Barone | M | 51 | 3 years | |
| Michael E. Paolucci | M | 64 | 5 years | |
| Thomas Woiwode | M | 52 | 5 years | |
| Jean Bizzari | M | 69 | 9 years | |
| Jim Mazzola | M | - | 3 years | |
| Robert Engler | M | 79 | 11 years | |
| Tadataka Yamada | M | 77 | 4 years | |
| John Stuart Patton | M | 77 | 25 years | |
| Eric Carter | M | 72 | 4 years | |
| Homa Yeganegi | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Athena Countouriotis
- Personal Network
